Altimmune to Participate at Two Investor Conferences in March

GAITHERSBURG, Md., March 06, 2018 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, announced today that Bill Enright, President and Chief Executive Officer, will provide a corporate overview at the 30th Annual ROTH Conference and the B. Riley FBR Inaugural China Healthcare Investing & Partnering Symposium.

About AltimmuneAltimmune is a clinical-stage immunotherapeutics company focused on the development of products to stimulate robust and durable immune responses for the prevention and treatment of disease including, NasoVAX, a Phase 2 seasonal influenza vaccine candidate, and HepTcell, a Phase 1 immunotherapeutic candidate for the potential cure of chronic hepatitis B. The company also has two United States government funded, next-generation anthrax vaccine candidates that are intended to improve protection and safety while having favorable dosage and storage requirements compared to other anthrax vaccines.

Contacts:Bill EnrightPresident and CEOPhone: 240-654-1450Email: [email protected]

Ashley RobinsonManaging Director LifeSci AdvisorsPhone: 617-535-7742Email: [email protected]

You May Also Be Interested In

• New to The Street Expands Global Audience, Surpassing 100,000 Subscribers Across MENA and Latin America
• Marquis Holdings Appoints Veteran Canadian Mining Executive John Hick as Senior Adviser
• GSJJ Expands Its Custom Keychain Production Line and Releases Technical Procurement Standards